MedTrace Logo

Optimizing Strategy of Coronary Revascularization in Patients With Multivessel Lesions Combined Heart Failure

NCT02775578 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 525

Last updated 2016-05-18

No results posted yet for this study

Summary

As the end stage of almost all cardiovascular diseases, heart failure has become an increasingly common cause of cardiovascular morbidity and mortality worldwide. In China, coronary artery disease (CAD) has become the main cause of heart failure in recent years. CAD combining with heart failure usually predicts poor outcome, with coronary revascularization the most universally used therapy. However, the difference of several types of such therapy has less well been compared.

Thus, the study mainly aims to compare different types of coronary revascularization therapies such as Percutaneous Coronary Intervention (PCI),Coronary Artery Bypass Grafting (CABG) as well as Hybrid Coronary Revascularization (HCR), and also make the optimization strategy especially in patients with heart failure.

The study also aims to investigate whether disease progression in patients with chronic heart failure (CHF) can be assessed by new biomarkers and determine their diagnostic and prognostic value, relating several cardiac functional parameters to clinical outcome.

Conditions

  • Heart Failure Due to Coronary Artery Disease

Interventions

PROCEDURE

Coronary Artery Bypass Grafting

Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.

PROCEDURE

Percutaneous Coronary Intervention

Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.

PROCEDURE

Hybrid Coronary Revascularization

Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775578 on ClinicalTrials.gov